Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Rheumatology · J Rheumatol · 2026-11-01
Secondary analysisn = 1,698
Nikiphorou et al. Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic ArthritisRheumatology · Rheumatology (Oxford) · 2026-10-01
RCTn = 66
Bosch et al. Efficacy and safety of probiotic supplementation in PsA-a randomized controlled trialRheumatology · Rheumatology (Oxford) · 2026-10-01
Secondary analysis
Rudwaleit et al. Bimekizumab efficacy in male and female patients with axial spondyloarthritis: 52-week results from the phase 3 BE MOBILE trialsRheumatology · J Rheumatol · 2026-10-01
RCTn = 574
Baraliakos et al. Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results From 2 Phase III StudiesRheumatology · RMD Open · 2026-08-27
Secondary analysisn = 195
Coates et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF: post hoc analysis of SELECT-PsA 2Rheumatology · Ann Rheum Dis · 2026-08-07
RCTn = 670
van der Heijde et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trialRheumatology · Rheumatology (Oxford) · 2026-08-01
RCTn = 249
Hammond et al. The WORKWELL programme: a randomized controlled trial of job retention vocational rehabilitation for people with inflammatory arthritisRheumatology · Rheumatology (Oxford) · 2026-08-01
Meta-analysisn = 51 studies
Du et al. Vaccination coverage of influenza and pneumococcal vaccines in patients with rheumatic diseases: a systematic review and meta-analysisRheumatology · J Rheumatol · 2026-08-01
Meta-analysisn = 6,171
Doumeth et al. Achieving Axial Spondyloarthritis Disease Activity Score Inactive Disease Status in Axial Spondyloarthritis in Clinical Trials: A Systematic Review and MetaanalysisRheumatology · Semin Arthritis Rheum · 2026-07-14
Meta-analysisn = 84 studies
Webers et al. Definition and prevalence of residual disease in inflammatory arthritis: a systematic literature review and meta-analysisRheumatology · Rheumatology (Oxford) · 2026-06-30
Guideline
Scott et al. The 2026 British Society for Rheumatology guideline for pain management in people with inflammatory arthritisRheumatology · Rheumatology (Oxford) · 2026-06-30
Secondary analysisn = 308
Coates et al. Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: Novel insights from FOREMOSTRheumatology · Rheumatology (Oxford) · 2026-06-30
Secondary analysisn = 31
De Marco et al. Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active PsA: data from the GOLMePsA clinical trialRheumatology · Lancet Rheumatol · 2026-06-29
RCTn = 502
Chen et al. Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase 3 trialRheumatology · Ann Rheum Dis · 2026-06-25
Secondary analysis
Baraliakos et al. Comparison of the established ASAS definition and preliminary proposed data-driven cut-offs for inflammatory and structural MRI lesions in the sacroiliac joints for eligibility of patients with nonradiographic axial spondyloarthritis in clinical trialsRheumatology · Ann Rheum Dis · 2026-06-05
Meta-analysisn = 24 trials
Annfeldt et al. Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysisRheumatology · Rheumatology (Oxford) · 2026-06-03
Meta-analysisn = 2,300
Tomo et al. Cycling versus swapping strategies for treatment of psoriatic arthritis after primary tumour necrosis factor inhibitors failure: a systematic review and meta-analysisRheumatology · RMD Open · 2026-05-21
RCTn = 147
Maksymowych et al. Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitisRheumatology · RMD Open · 2026-05-13
RCTn = 586
Navarro-Compán et al. Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extensionRheumatology · Arthritis Rheumatol · 2026-05-11
RCTn = 91
Scher et al. Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept Study